The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Morgan Stanley has expanded its series of price target revisions to include the banking and utility sectors, lowering its target for U.S. Bancorp (USB) to $64 from $65 while maintaining an Equalweight rating. The bank also adjusted its price target for Sempra (SRE) slightly downward to $104 from $105, keeping an Overweight rating. These updates follow the bank's decision to reiterate an Equalweight rating for Pfizer (PFE) at $28.00 following exclusivity extensions for Vyndamax. Previously, the bank raised its target for Kroger (KR) to $73, while lowering targets for Thermo Fisher (TMO) to $620 and NetApp (NTAP) to $88. These revisions reflect a broader recalibration of valuation models to account for shifting dynamics across healthcare, technology, and financial services.
Sign in to access this content
Sign In